TLC-ART’s DcNP a Platform Validation
TLC-ART’s innovative technology has now been validated to enable to produce long-acting, targeting multiple drugs simultaneously to HIV-host cells, & to allow a single-dose to carry 3-4 drugs. The following boxes demonstrate platform capabilities and validation.
a, DcNP; Drug combination Nano-Particle platform developed by the TLC-ART Program
b, LPV, Lopinavir; RTV, Ritonavir; 3TC, Lamivudine; EFV, Efavirenz; TFV, Tenofovir
c, PBMC found in the blood that can be HIV infected